Limits...
Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.

Mukherjee A, Shehata M, Moseley P, Rakha E, Ellis I, Chan S - Br. J. Cancer (2010)

Bottom Line: Protein expression of nine biomarkers (topoisomerase2α (Topo2α), ER, PR, HER2, Ki67, p53, EGFR, CK5/6 and CK14) was assessed in pre-chemotherapy core biopsies using immunohistochemistry (IHC) and results correlated with clinical and pathological response. clinical (cCR) and pathological (pCR) complete response were seen in 34.1% (n=31) and 20% (n=18), respectively.Pathological complete response was concordant with cCR in 14/31 cases; in four cases of cPR with palpable residual breast tumours, histology showed fibrous tissue only (pCR).Positivity for p53 also showed significance (P=0.015), whereas basal phenotype, HER2, and all the clinicopathological variables of LAPC included in this study did not show significant correlation with response.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Nottingham University Hospitals, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK.

Show MeSH

Related in: MedlinePlus

Overall survival (A) and relapse-free survival (B) analysis for patients either positive or negative for basal phenotype (BP).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3008601&req=5

fig3: Overall survival (A) and relapse-free survival (B) analysis for patients either positive or negative for basal phenotype (BP).

Mentions: Of the relapses and deaths, 19 (61%) and 10 (47%) were Topo2α-high, respectively. However, Topo2α status did not predict either relapse-free (P=0.67) or OS (P=0.76) (Figure 2A and B). Similarly, although patients with BP tumours tend to have a worse OS and RFS, this was not statistically significant (P=0.5 and P=0.54, respectively) (Figure 3A and B).


Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.

Mukherjee A, Shehata M, Moseley P, Rakha E, Ellis I, Chan S - Br. J. Cancer (2010)

Overall survival (A) and relapse-free survival (B) analysis for patients either positive or negative for basal phenotype (BP).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3008601&req=5

fig3: Overall survival (A) and relapse-free survival (B) analysis for patients either positive or negative for basal phenotype (BP).
Mentions: Of the relapses and deaths, 19 (61%) and 10 (47%) were Topo2α-high, respectively. However, Topo2α status did not predict either relapse-free (P=0.67) or OS (P=0.76) (Figure 2A and B). Similarly, although patients with BP tumours tend to have a worse OS and RFS, this was not statistically significant (P=0.5 and P=0.54, respectively) (Figure 3A and B).

Bottom Line: Protein expression of nine biomarkers (topoisomerase2α (Topo2α), ER, PR, HER2, Ki67, p53, EGFR, CK5/6 and CK14) was assessed in pre-chemotherapy core biopsies using immunohistochemistry (IHC) and results correlated with clinical and pathological response. clinical (cCR) and pathological (pCR) complete response were seen in 34.1% (n=31) and 20% (n=18), respectively.Pathological complete response was concordant with cCR in 14/31 cases; in four cases of cPR with palpable residual breast tumours, histology showed fibrous tissue only (pCR).Positivity for p53 also showed significance (P=0.015), whereas basal phenotype, HER2, and all the clinicopathological variables of LAPC included in this study did not show significant correlation with response.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Nottingham University Hospitals, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK.

Show MeSH
Related in: MedlinePlus